Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
about
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.Endocannabinoids in liver disease.Current and future drug targets in weight managementThe case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley ratsBeneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.Does rimonabant independently affect free fatty acid and glucose metabolism?Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates.Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.CB1 receptor antagonists: new discoveries leading to new perspectives.Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.The cannabinoid receptor 1 and its role in influencing peripheral metabolism.Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions.Pro-inflammatory obesity in aged cannabinoid-2 receptor-deficient mice.Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.
P2860
Q34028741-DA9A8E36-BBC4-472E-B68B-E371D4ED8C9AQ34776919-E8CEBD07-97DF-4389-8732-382FD5BF052BQ35089784-FB5288D1-657B-48AA-AC06-14B753C0736FQ35193287-52EAA27D-B69D-4E84-A3EB-3CC2E05C6FEBQ35223942-4B07361B-2FB9-44F6-8020-50A8A0ECA6ADQ35860311-6F6135AC-4FA4-4D69-8F5B-4B96AD814ACFQ35869688-04E85024-381C-417F-AAD3-5BC39BA15F74Q36309433-D7187998-1B59-46C9-801D-34EE18E581FDQ36373581-833C2381-A5CC-4AE0-A63F-9A82AC2DDE10Q37581457-0EF82527-2366-41D1-AC32-8973D7028CA3Q37998561-2978244D-AB76-4441-939A-C28EA573E9D5Q38025166-02F2005D-FACB-44A4-B650-E5BB69A5DE59Q38031743-8C9E847A-7376-435D-82E7-0699C95DEA39Q38115637-6F4D17D3-57C7-4C72-9119-E85376246E6DQ38924783-7AB8605A-3AB4-4500-8E74-29DCDEB653D6Q42823729-B15966EB-A10E-4C72-9BE5-4E7BD1B65DE0Q44010230-136E3D87-73A7-4AA3-A77C-1B91D5870CAFQ45288843-45A24E16-C2DE-4EE4-A066-102ECA9B5E7B
P2860
Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Peripherally acting CB1-recept ...... eceptors in adiposity control.
@en
type
label
Peripherally acting CB1-recept ...... eceptors in adiposity control.
@en
prefLabel
Peripherally acting CB1-recept ...... eceptors in adiposity control.
@en
P2093
P2860
P356
P1476
Peripherally acting CB1-recept ...... eceptors in adiposity control.
@en
P2093
P2860
P2888
P304
P356
10.1038/IJO.2009.253
P407
P577
2009-12-22T00:00:00Z
P5875
P6179
1042010231